Akanda (NASDAQ:AKAN) stock is on the rise Friday as the company’s shares continue a rally that started yesterday.
That rally was kicked off by an update from the U.S. Food and Drug Administration (FDA). The agency called for a change to the framework surrounding cannabidiol (CBD). This could see updates to the legal standing of CBD that might benefit AKAN stock and other companies in the business.
When that news broke yesterday, it sent shares of AKAN stock soaring up to 200% higher. However, the stock didn’t remain that high. Instead, it closed out Thursday with shares up 47.4%.
Trading was also heavy that day with some 130 million shares on the move. That’s a massive surge in trading volume compared to the CBD company’s daily average of 3 million shares.
How AKAN Stock Is Moving on Friday
With the rally continuing, shares of AKAN stock are continuing to see heavy trading volume today, though not nearly as much as yesterday. As of this writing, more than 10 million shares of the stock have been traded.
AKAN stock is up 31% in pre-market trading on Friday. The company’s stock is also up 86.7% since the start of the year.
Investors seeking out more of the latest stock market news will want to keep reading!
We’ve got all of the hottest stock market news traders need to know about on Friday! Among that is what has shares of Redhill Biopharma (NASDAQ:RDHL) stock rising, this morning’s biggest pre-market stock movers, and more. You can check out all that news at the links below!
More Friday Stock Market News
- Why Is Redhill Biopharma (RDHL) Stock Up 32% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
- Occupy SEC 2023: Mark Your Calendars for Jan. 27
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.